BIOTYPE GmbH and STRATIFYER Molecular Pathology GmbH agree on strategic collaboration to advance precision medicine for bladder cancer patients
The focus is particularly on advances in the targeted therapy of bladder cancer patients, especially in the case of alterations in FGFR genes. STRATIFYER will contribute its many years of experience in translational research and clinical trials, while BIOTYPE will enable automated biomarker analyses using the MODAPLEX platform. The aim of this strategic collaboration is to facilitate access to precision medicine and improve the quality of life of patients with bladder cancer.
Bladder cancer is a common malignancy that generates significant healthcare costs due to the lifelong monitoring required. Recent breakthroughs in clinical trials have demonstrated the benefit of targeted therapies for patients with advanced or metastatic urothelial carcinoma, particularly those with alterations in FGFR genes. The collaboration between BIOTYPE and STRATIFYER aims to capitalise on these advances to support the current paradigm shift in the treatment of bladder cancer patients.
STRATIFYER is known for its many years of experience in the field of translational research, which it brings to the collaboration both in the design of clinical trials and in clinical research. In particular, the company's bladder cancer registry study, known as BLADDER BRIDGister, has validated decision-relevant molecular markers that enable the targeted selection of therapy options. STRATIFYER will use this data to support the development of assays for in vitro diagnostics.
BIOTYPE, a vertically integrated in-vitro diagnostics and medical device company, is characterised by the development, manufacture and distribution of products and systems for molecular diagnostics and nucleic acid analysis. With its proprietary MODAPLEX platform, BIOTYPE offers automated analysis of biomarker signatures. Building on STRATIFYER's research results, BIOTYPE will develop in vitro diagnostic assays for the MODAPLEX platform. This collaboration aims to enable the rapid, cost-effective and automated detection of decision-relevant biomarker signatures for precision oncology.
The initial focus of the partnership is on the development of novel assays for the „molecular profiling“ of FGFR-specific biomarker signatures. In addition to the standard FGFR mutation/fusion analysis, additional therapy candidates for targeted FGFR therapies and treatment combinations will be identified. These assays will be validated in large patient cohorts in clinical trials. By performing multi-layered precision diagnostics that modularly analyses mutations, fusions, expression levels and amplifications of potential target genes simultaneously on one platform, patients gain access to in-depth precision medicine.
"We are excited to work with STRATIFYER to improve precision medicine for bladder cancer patients," said Dr Norman Gerstner, CEO of BIOTYPE. "This collaboration brings together the complementary strengths of both companies and allows us to combine our respective expertise for the development of innovative diagnostic tests. Together, we want to improve the prospects of therapeutic success for patients with bladder cancer and support the further development of diagnostics in this field."
Dr Ralph M. Wirtz, CEO of STRATIFYER, said: "Our collaboration with BIOTYPE represents a unique opportunity to translate our research findings into highly relevant diagnostics that will benefit patients with bladder cancer. By combining our extensive clinical expertise with BIOTYPE's cutting-edge technology, we aim to open up new possibilities for precision medicine and drive progress in this field."
The strategic collaboration between BIOTYPE GmbH and STRATIFYER Molecular Pathology GmbH harbours great opportunities for the future of bladder cancer diagnosis and treatment. Through their joint endeavours, the two German companies aim to facilitate access to precision medicine and ultimately improve the quality of life of patients with bladder cancer.
For more information about BIOTYPE GmbH, please visit:
https://www.biotype.de/en/home.html
For more information about STRATIFYER Molecular Pathology GmbH please visit:
Press release from 21 July 2023
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.